This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rubius Therapeutics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.1yrs

최근 관리 업데이트

Recent updates

CEO

Craig Jalbert (61 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert, CIRA is President, Treasurer, Corporate Secretary & Director of Aptinyx Inc. since May 04, 2023. He is President, Treasurer, Corporate Secretary, Principal Executive Officer, Interim...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Craig Jalbert	President	less than a year	데이터 없음	데이터 없음
Michael Rosenblatt	Independent Director	8.5yrs	US$421.66k	0% € 0
Robert Langer	Member of Scientific Advisory Board	8.5yrs	US$850.74k	데이터 없음
Harvey Lodish	Scientific Advisory Board	5.3yrs	US$24.00k	데이터 없음
Gerald Nepom	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Vijay Kuchroo	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Susanne Schaffert	Director	less than a year	데이터 없음	데이터 없음
Francis Cuss	Independent Director	5.4yrs	US$426.66k	0% € 0
Christopher Carpenter	Member of Scientific Advisory Board	3.4yrs	US$2.84m	데이터 없음
Christopher Hunter	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
John Monroe	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: 5RT 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

This company listing is no longer active

Rubius Therapeutics 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Recent updates

Less than half of directors are independent

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: €12.50

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €8.10

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: €7.90

New 90-day high: €4.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €3.84

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: €3.92

New 90-day low - €4.00

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €4.92

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령